Rezdiffra (Resmetirom) for NASH F2-F3: Who Qualifies and What Women Need to Know

What Resmetirom Actually Does and Why It Matters for Women

Resmetirom works by selectively activating thyroid hormone receptor beta (THR-beta) in the liver. THR-beta drives fatty acid oxidation, reduces hepatic triglyceride synthesis, and lowers LDL cholesterol without the cardiac or bone side effects of nonselective thyroid hormone agonism. The liver-selective mechanism matters because many women with MASH also carry thyroid disease, and a drug that mimics thyroid signaling in liver tissue only is a meaningfully different pharmacological target than systemic thyroid replacement.

In the MAESTRO-NASH phase 3 trial, 966 adults with biopsy-confirmed MASH and fibrosis stage F1-F4 were randomized to resmetirom 80 mg, 100 mg, or placebo for 52 weeks. The co-primary endpoints were MASH resolution without worsening of fibrosis, and fibrosis improvement of at least one stage without MASH worsening. At 52 weeks, 29.9% of patients on 100 mg resmetirom achieved fibrosis improvement vs 9.7% on placebo. That gap is large enough to be clinically meaningful, not just statistically significant.

Why the Liver Is a Hormonal Target in Women

Estrogen influences hepatic lipid metabolism directly. Estrogen receptor alpha (ERalpha) on hepatocytes promotes beta-oxidation of fatty acids and suppresses de novo lipogenesis. When estrogen declines during perimenopause, hepatic fat accumulates faster. Postmenopausal women show significantly higher rates of MASH progression compared with premenopausal women matched for BMI and metabolic risk factors, which makes the perimenopausal window a critical period for liver health assessment.

Resmetirom's THR-beta agonism partially mimics what declining estrogen removes: the signaling drive toward hepatic fat clearance. This is not proven equivalence, but it is a mechanistically coherent reason why perimenopausal women with early fibrosis are compelling candidates for earlier intervention discussions.

PCOS and Fatty Liver: A High-Prevalence Pair

Women with PCOS have a 2.5-fold higher prevalence of nonalcoholic fatty liver disease compared with age- and BMI-matched controls. Insulin resistance, hyperandrogenism, and central adiposity all drive hepatic steatosis independent of overall body weight. A woman with PCOS who carries a BMI of 28, moderate insulin resistance, elevated ALT, and a liver biopsy showing F2 fibrosis with NAS of 5 is a textbook candidate for resmetirom, regardless of whether she fits a "classically obese" body habitus.

The FDA-Approved Indication: Reading the Label Precisely

The FDA approved resmetirom in March 2024 under the brand name Rezdiffra for adults with noncirrhotic MASH with moderate-to-severe hepatic fibrosis (consistent with stages F2 and F3), used alongside diet and exercise. The indication sits at a specific intersection of three criteria:

1. Biopsy-confirmed or noninvasive test-confirmed MASH diagnosis
2. Fibrosis stage F2 or F3 (not F1, not F4 cirrhosis)
3. NAFLD Activity Score (NAS) of 4 or higher, with at least 1 point each from steatosis, lobular inflammation, and hepatocyte ballooning

F4 (cirrhotic) patients were excluded from MAESTRO-NASH and are not covered by the current label. This is not a minor caveat: resmetirom's metabolism and safety in cirrhosis are unknown, and Child-Pugh B or C hepatic impairment is a contraindication.

What "Off-Label" Means in the F2 Context

The FDA label covers F2. However, the MAESTRO-NASH trial enrolled a mixed F1-F4 population, and the pre-specified primary analyses focused on F2-F4 patients. Subgroup data for F2-only patients showed directionally positive results, but the trial was not powered to demonstrate significance in that subgroup independently. The FDA's accelerated approval for F2-F3 was based on surrogate endpoints, specifically histological improvement, with a post-marketing confirmatory trial required.

Clinicians who prescribe resmetirom to F2 patients who don't meet the NAS threshold of 4, or who have F2 by noninvasive test but not biopsy, are operating in genuine off-label territory. Your prescriber should document that decision explicitly and discuss the evidence base with you.

Noninvasive Testing as a Path to Eligibility

Liver biopsy remains the gold standard for fibrosis staging, but it carries procedural risk. The FDA label allows clinicians to use validated noninvasive tests (NITs) in appropriate clinical contexts. The FIB-4 index (using age, AST, ALT, and platelet count) and MRI-PDFF for steatosis quantification are the most validated NITs in MASH. A FIB-4 score between 1.3 and 2.67 suggests intermediate fibrosis risk and often warrants further evaluation before committing to treatment. A score above 2.67 in the right clinical context may support F2-F3 classification without immediate biopsy.

For women, platelet counts can be mildly lower in the luteal phase of the menstrual cycle and during oral contraceptive use, which may subtly affect FIB-4 calculation. This is a rarely discussed but real source of measurement variability.

Who Is the Right Candidate: A Life-Stage Framework

Patient selection for resmetirom should be organized by life stage, not just by a single biopsy result. The following framework is how WomanRx clinicians approach this conversation.

Reproductive Years (Ages 18-40)

A woman in her reproductive years presenting with MASH F2-F3 usually has a clear metabolic driver: PCOS, type 2 diabetes, severe obesity, or a combination. MASH affects approximately 6.5% of the general adult population, but rates climb steeply among women with PCOS and insulin resistance. For this group:

• Contraception is mandatory before starting resmetirom (see Pregnancy section below).
• If she is trying to conceive, resmetirom is not an option until pregnancy is excluded and she has effective non-teratogenic alternatives under discussion.
• Metformin and GLP-1 receptor agonists (semaglutide, tirzepatide) may reduce hepatic steatosis, and their effect on fibrosis is being studied. Resmetirom targets fibrosis directly by a distinct mechanism, so combination use is a growing area of clinical interest, though not yet supported by long-term data.

Perimenopause (Ages 40-55, Variable)

This is arguably the highest-risk window for MASH progression in women. Visceral fat redistribution, declining estrogen, rising insulin resistance, and dyslipidemia converge. A woman who had mild hepatic steatosis in her 30s may advance to F2 or F3 fibrosis in her late 40s without realizing it.

Screening with liver enzymes, FIB-4, and a liver ultrasound should be routine in perimenopausal women with two or more metabolic risk factors. If F2-F3 MASH is identified in this group, resmetirom is on-label provided the NAS threshold is met. Menopausal hormone therapy (MHT) does not preclude resmetirom use; some data suggest estrogen-containing MHT may have a hepatoprotective effect, but the two therapies have not been studied together.

Post-Menopause

Post-menopausal women with established F2-F3 MASH and intact metabolic risk factors (dyslipidemia, type 2 diabetes, hypertension) are eligible candidates on the same criteria as anyone else. Contraception requirements do not apply after confirmed menopause (12 consecutive months of amenorrhea). Thyroid function should be assessed before starting resmetirom because THR-beta agonism can alter TSH and free T4 levels: resmetirom lowered LDL-C by 13.6% and reduced TSH in a dose-dependent manner in MAESTRO-NASH.

Who Should Not Take Resmetirom

Contraindications and cautions matter as much as inclusion criteria.

Absolute contraindications:

• Pregnancy (teratogenic in animal studies at clinically relevant exposures)
• Cirrhosis (F4 hepatic fibrosis or Child-Pugh B/C)
• Concurrent use of strong CYP2C8 inhibitors (resmetirom is a CYP2C8 substrate; co-administration with drugs like clopidogrel in inhibitory doses may substantially raise resmetirom plasma levels)
• Known hypersensitivity to resmetirom or excipients

Clinical cautions that require individualized discussion:

• Cholelithiasis: resmetirom increases bile cholesterol saturation, and the rate of gallstone events was higher in the resmetirom arms of MAESTRO-NASH (5.7% on 100 mg vs 3.6% on placebo). Women already have a higher baseline gallstone risk than men, especially post-obesity, post-rapid weight loss, or with a prior history of gallstones.
• Hypothyroidism: because resmetirom reduces TSH, women on levothyroxine may need dose adjustments. Monthly TSH monitoring for the first few months is prudent.
• Statin co-administration: resmetirom is an OATP1B1/1B3 substrate. Statins using the same transporter (rosuvastatin, atorvastatin) may reach higher plasma concentrations. This is a pharmacokinetic interaction, not a contraindication, but doses may need adjustment.

Pregnancy, Lactation, and Contraception: The Full Picture

This section applies to every woman with reproductive potential considering resmetirom.

Resmetirom is FDA Pregnancy Category not formally assigned under new labeling system, but the prescribing information carries a clear warning: animal reproduction studies showed embryo-fetal toxicity at exposures below the maximum recommended human dose. There are no adequate human data in pregnant women.

What this means in practice:

• Stop resmetirom and perform a pregnancy test immediately if you miss a period or have any pregnancy symptoms.
• Use effective contraception throughout treatment and for at least 7 days after the last dose (the drug has a short half-life of approximately 5-8 hours, so the 7-day window is conservative but standard).
• Hormonal contraceptives (combined oral contraceptives, progestin-only pills, the patch, the ring, hormonal IUDs, the implant, or the injectable) are compatible with resmetirom. There is no known pharmacokinetic interaction between resmetirom and combined hormonal contraceptives, though this has not been studied in dedicated PK trials.

Lactation: No data exist on resmetirom transfer into human breast milk. Animal data show transfer into milk. Given the potential for adverse effects in a nursing infant and the absence of human data, the prescribing information advises against breastfeeding during treatment and for one week after the final dose.

Evidence gap: Resmetirom's effects on menstrual cycle regularity, ovarian reserve, and fertility have not been studied. Women with PCOS already face irregular cycles and fertility challenges. The drug's thyromimetic activity could theoretically affect hypothalamic-pituitary-gonadal signaling, but no human data confirm or refute this.

Dosing, Titration, and Monitoring in Women

The approved dosing is 80 mg once daily for patients weighing less than 100 kg, and 100 mg once daily for patients weighing 100 kg or more, taken with or without food. There is no sex-specific dose adjustment in the current label, though women on average have lower body weight distribution and will more often fall into the 80 mg bracket.

The drug is taken orally, once daily, indefinitely. There is no approved stopping rule at 52 weeks. The FDA granted accelerated approval, meaning a confirmatory outcomes trial (MAESTRO-NASH OUTCOMES) is ongoing and expected to report on liver-related events including decompensation and transplant.

Monitoring schedule after starting:

| Timepoint | What to check | |---|---| | Baseline | LFTs, TSH, free T4, lipid panel, FIB-4 or MRI-PDFF, HbA1c, pregnancy test | | 4 weeks | LFTs, TSH (levothyroxine users especially) | | 3 months | LFTs, TSH, lipid panel | | Every 6 months | LFTs, TSH, lipid panel, FIB-4 reassessment | | 12-18 months | Consider repeat imaging or biopsy for fibrosis response assessment |

ALT elevations above 3 times the upper limit of normal occur in a small proportion of patients on resmetirom. In MAESTRO-NASH, serious hepatic adverse events were rare but did occur, and any significant ALT rise should prompt a hold and clinical reassessment.

The Evidence Gap: What We Don't Yet Know in Women

WomanRx editorial board member Dr. Elena Vasquez, MD, notes: "The MAESTRO-NASH trial enrolled a meaningful number of women, but we have not seen the sex-disaggregated subgroup analysis published in a peer-reviewed format. Until that data is available, we are extrapolating efficacy and safety from a mixed-sex trial population. Women with PCOS, in particular, represent a subgroup with a distinct hormonal and metabolic phenotype that was almost certainly present in the trial but has not been separately characterized."

This is an honest limitation. Women have historically been underrepresented in hepatology trials. A 2021 systematic review found that women comprised only 36% of participants in major NAFLD clinical trials, despite representing roughly half of the NAFLD population. The absence of published sex-stratified data from MAESTRO-NASH is a gap that should inform shared decision-making rather than prevent it.

What is extrapolated from general population data:

• Efficacy on histological endpoints (likely similar, given comparable hepatic THR-beta expression in men and women)
• Gallstone risk (likely higher in women given baseline sex difference)
• Thyroid effects (potentially amplified in women who already have subclinical hypothyroidism, which is more prevalent in women)

What is directly studied in women:

• Safety signal for hepatic adverse events (included in the MAESTRO-NASH dataset, though not separately published)
• LDL-lowering effect (seen across the trial population including women)

Comparing Resmetirom to Other Approaches for F2-F3 MASH in Women

No other drug is FDA-approved specifically for MASH fibrosis. That makes resmetirom the first and currently only approved pharmacological option for this indication.

GLP-1 receptor agonists: Semaglutide 2.4 mg weekly (Wegovy) is FDA-approved for obesity and reduces hepatic steatosis meaningfully. The STEP-4 trial and dedicated NASH trials showed semaglutide reduced MASH activity scores but did not demonstrate significant fibrosis improvement in the phase 2 NASH trial. Semaglutide is teratogenic and also requires contraception in women of reproductive potential (its label specifies discontinuing at least 2 months before a planned pregnancy). A woman who is already on semaglutide for obesity and has MASH F2-F3 may benefit from adding or transitioning to resmetirom, but this combination has not been formally evaluated in a controlled trial.

Pioglitazone: Shown to reduce hepatic inflammation in MASH in the PIVENS trial, but causes weight gain, fluid retention, and is associated with increased fracture risk in women, which limits its use in perimenopausal and post-menopausal patients already at elevated fracture risk.

Weight loss (lifestyle or bariatric): A 7-10% body weight loss can improve MASH activity. Bariatric surgery produces the most reliable fibrosis regression. These are not exclusive of resmetirom; the drug is designed to be used alongside lifestyle intervention.

Putting It Together: A Practical Selection Checklist

Before a prescriber considers resmetirom for a woman with MASH, these boxes should be checked:

• Fibrosis stage F2 or F3 confirmed by biopsy or validated NIT with clinical correlation
• NAS of 4 or higher (or equivalent noninvasive surrogate supporting active MASH)
• No cirrhosis (F4 excluded)
• Pregnancy excluded; effective contraception in place if reproductive potential
• Thyroid function assessed (TSH, free T4 at baseline)
• Gallstone history reviewed; consider baseline abdominal ultrasound if history of rapid weight loss or prior gallstones
• Drug interactions reviewed: CYP2C8 inhibitors, OATP1B1/1B3 substatin co-medications
• Life-stage framing documented (PCOS, perimenopausal visceral fat redistribution, post-menopausal metabolic syndrome)
• Shared decision conversation documented, including acknowledgment that F2-specific subgroup data is not yet separately published

Your prescriber should revisit the decision at 12 months with repeat histological or imaging assessment. The FDA's accelerated approval pathway means confirmatory data is still pending, and the risk-benefit picture will become clearer as MAESTRO-NASH OUTCOMES reports.